Omega-3s and Fish Oil: Sorting the Evidence from the Hype

What omega-3s are

Omega-3 fatty acids - mainly EPA and DHA from fatty fish - are essential fats your body cannot make efficiently. They are among the best-studied supplements on the market. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the long-chain omega-3s found in salmon, sardines, mackerel, herring and anchovies. A third omega-3, ALA (alpha-linolenic acid), comes from flaxseed, chia and walnuts.

That distinction matters more than the marketing suggests. Stable-isotope tracer studies show the body converts only a small fraction of ALA into EPA, and conversion onward to DHA is very low (Burdge & Calder 2005). ALA from flaxseed converts poorly to EPA/DHA - plant omega-3s are not equivalent to fish or fish oil.

How they work, in plain words

EPA and DHA are built into the membranes of nearly every cell, where they compete with omega-6 fats for the same enzymes. That competition shifts the signalling molecules cells make toward less inflammatory ones. In the liver, EPA and DHA also slow the packaging of triglycerides into the particles that carry fat through the blood, which is why the triglyceride effect is the most reliable and dose-dependent thing omega-3s do. Effects on heart rhythm and platelet stickiness are plausible but less consistent.

Heart health: the strongest case

A 2025 systematic review and meta-analysis found omega-3s associated with significant reductions in cardiovascular disease, coronary disease, and cardiac death (Mattumpuram 2025, Clin Transl Discov). The nuance: EPA-heavy formulas showed clearer benefit than EPA+DHA combinations in some high-risk groups. One real caveat - high-dose supplements may modestly raise the risk of atrial fibrillation, so more is not automatically better.

The individual trials behind those pooled numbers tell a more textured story:

• REDUCE-IT (Bhatt et al. 2019) enrolled 8,179 statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes. Prescription icosapent ethyl (purified EPA) at 4 g/day, followed for a median of 4.9 years, cut the primary composite of cardiovascular events from 22.0% to 17.2% - a 25% relative reduction. This was a drug trial at a prescription dose in high-risk patients, not a supplement-dose result, and the trial was funded by the manufacturer.
• STRENGTH (Nicholls et al. 2020) tested 4 g/day of a prescription EPA+DHA formulation against corn oil in 13,078 similar high-risk patients. It was stopped early for futility: 12.0% versus 12.2% had a primary event. Why one trial succeeded and the other failed - EPA-only versus EPA+DHA, the mineral-oil placebo in REDUCE-IT, or chance - is still debated.
• VITAL (Manson et al. 2019) is the closest thing to a test of everyday supplement use: 25,871 US adults without cardiovascular disease took 1 g/day of prescription-grade fish oil for a median of 5.3 years. Major cardiovascular events were not significantly reduced (hazard ratio 0.92), although total heart attacks were lower in a secondary analysis (hazard ratio 0.72). Cancer incidence was unchanged.
• A meta-analysis of 13 randomized trials and 127,477 participants (Hu et al. 2019) found small but consistent reductions even after excluding REDUCE-IT: about 8% lower heart-attack and coronary-death risk and 7% lower cardiovascular-death risk, with benefit rising in a roughly linear way with dose.

Put together: at ordinary supplement doses the benefit is real but small; the large 25% effect comes from one prescription-dose EPA trial that has not been replicated.

The atrial fibrillation trade-off

The clearest downside also comes from the big trials. A meta-analysis of seven cardiovascular-outcome RCTs covering 81,210 patients (Gencer et al. 2021) found marine omega-3 supplementation raised the risk of atrial fibrillation by about 25% overall. The effect was dose-dependent: roughly 12% higher risk in trials using 1 g/day or less, and 49% higher in trials using more than 1 g/day. In REDUCE-IT itself, hospitalisation for atrial fibrillation or flutter was 3.1% versus 2.1%. Atrial fibrillation is a heart-rhythm disturbance that raises stroke risk, which is the main reason mega-dosing without medical supervision is a poor idea.

Triglycerides and LDL: what changes on a blood test

The American Heart Association’s science advisory (Skulas-Ray et al. 2019) summarises the lipid effects of pharmacological doses. At prescription-level doses of 2–4 g/day EPA+DHA, omega-3s lower triglycerides by roughly 20–30%, and by 30% or more in people with very high triglycerides at 4 g/day. Typical supplement doses of a few hundred milligrams do far less.

LDL cholesterol is a different story. Fish oil does not reliably reduce LDL-C, and EPA+DHA products at 4 g/day actually raised LDL-C in people with very high triglycerides, whereas EPA-only did not. Lipid specialists generally read the DHA-related rise as a shift toward larger LDL particles rather than more of them, which is considered roughly neutral - but anyone tracking LDL-C or ApoB should know the number can move. For why particle count matters more than LDL-C alone, see ApoB vs LDL.

Brain health: weaker than marketed

Despite the “brain food” reputation, omega-3 supplements have not reliably improved cognition in healthy older adults - trial reviews find no consistent effect (Welty 2023). Of 15 randomized trials in cognitively healthy people over 55, seven reported a benefit and eight did not. The evidence is a little more hopeful for people who already have cognitive impairment, but supplementation is not a proven prevention. DHA trials in people with mild cognitive impairment showed some slowing of decline, while trials in Alzheimer’s disease found none.

Food first

Eating fatty fish such as salmon, sardines, or mackerel twice a week is the most evidence-backed way to get omega-3s. The American Heart Association’s seafood advisory (Rimm et al. 2018) lands in the same place: one to two seafood meals per week, especially when fish replaces less healthy foods. A single serving of oily fish typically delivers more EPA and DHA than a standard fish-oil capsule.

Supplements make sense if you do not eat fish; choose a reputable, third-party-tested brand to avoid rancidity and contaminants.

What the studies used

These are the amounts trials used, not a recommendation.

A few practical points that follow from the trials:

• Read the EPA+DHA content, not the “fish oil” headline number - a 1,000 mg fish-oil capsule usually contains well under 1,000 mg of EPA+DHA.
• Absorption is better with a meal that contains some fat.
• Store capsules away from heat and light; oxidised fish oil tastes and smells rancid and is one reason third-party testing matters.
• If the goal is a triglyceride number, that is a prescription conversation with a clinician, not a supplement decision.

For weighing this kind of evidence, see how to read a supplement study.

Safety and interactions

• Digestive effects are the most common complaint: fishy aftertaste, loose stools and nausea. In STRENGTH, 24.7% of the 4 g/day group reported gastrointestinal adverse events versus 14.7% on corn oil.
• Atrial fibrillation risk rises with dose, as above.
• Bleeding: omega-3s mildly reduce platelet stickiness. In REDUCE-IT, serious bleeding was 2.7% versus 2.1% (not statistically significant); VITAL saw no excess bleeding at 1 g/day. People on anticoagulants or antiplatelet drugs should still raise it with their prescriber.
• LDL-C can rise with high-dose DHA-containing products.
• Allergy: fish and shellfish allergies are a reason to check the source.

Talk to a clinician before supplementing if you have a history of atrial fibrillation or other heart-rhythm problems, take blood thinners, have surgery scheduled, are pregnant or breastfeeding, or have high triglycerides that have not been evaluated. Note that VITAL also tested vitamin D in the same participants, with a similarly null primary result - see vitamin D supplementation.

Bottom line

Omega-3s earn their reputation for heart health, especially from food and in higher-risk people. The cognitive claims outrun the data, and very high doses carry an atrial-fibrillation trade-off. The trial record is honest about the size of the effect: small at everyday supplement doses, larger only in one prescription-dose EPA trial in high-risk patients. Aim for fish first, supplement sensibly, and skip mega-doses unless a doctor directs them.